Top Markets
Coin of the day
CytoMed Therapeutics Limited CytoMed Therapeutics Limited

CytoMed Therapeutics Limited

GDTC
주식 순위 #32327
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical... CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
주가
$0.88
마지막 동기화: 2026-08-17
시가총액
$10.41M
변동 (1일)
-7.26%
변동 (1년)
-50.56%
국가
SG
거래 CytoMed Therapeutics Limited (GDTC)

카테고리

CytoMed Therapeutics Limited (GDTC)의 수익
2026 기준 수익 TTM: 0
CytoMed Therapeutics Limited의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
CytoMed Therapeutics Limited의 수익 기록 (2026 ~ 2026)
연말 수익
연도 수익 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
$3.01B -
BE